User:Mr. Ibrahem/Teprotumumab

Teprotumumab, sold under the brand name Tepezza, is a medication used to treat thyroid eye disease (TED). It decreases eye protrusion (proptosis). It is given by slow injection into a vein.

Common side effects include muscle spasm, nausea, hair loss, diarrhea, fatigue, high blood sugar, hearing loss, dry skin, altered taste, and headache. Other side effects may include Infusion reactions. It should not be used during or for the six months prior to pregnant. It is a human monoclonal antibody which binds to insulin-like growth factor-1 receptor (IGF-1R) thereby preventing its activation.

Teprotumumab was approved for medical use in the United States in 2020. As of 2021 it is not approved in Europe. In the United States it costs about 15,600 USD per 500 mg vial as of 2021.